A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors
This is an open-label Phase 1 dose escalation and expansion study of OMP-305B83 in subjects with previously treated solid tumors. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.
Advanced Solid Tumor Malignancies
DRUG: OMP-305B83
Incidence of dose limiting toxicities (DLTs), Number of subjects with a DLT, Subjects will be assessed for DLTs from Days 0-21. Adverse events will be reported through 30 days after discontinuation of treatment|Incidence of adverse events, Number of subjects with adverse events, Up to 2 years
Pharmacokinetics (PK) - AUC, Clearance, volume of distribution, apparent half-life, Area under the plasma concentration-time curve, measurement of renal clearance from the body, volume of distribution, apparent half life of antibody, PK analyses at various time points following the 1st and 3rd doses, pre-dose at Day 84 and every 9 weeks while on study, at treatment term, every 6 weeks for 12 weeks post termination
This is an open-label Phase 1 dose escalation and expansion study of OMP-305B83 in subjects with previously treated solid tumors. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.